JP2007532605A - 冠性心疾患または冠状動脈疾患を持つ患者の鬱病の予防および／または治療における必須脂肪酸 - Google Patents
冠性心疾患または冠状動脈疾患を持つ患者の鬱病の予防および／または治療における必須脂肪酸 Download PDFInfo
- Publication number
- JP2007532605A JP2007532605A JP2007507767A JP2007507767A JP2007532605A JP 2007532605 A JP2007532605 A JP 2007532605A JP 2007507767 A JP2007507767 A JP 2007507767A JP 2007507767 A JP2007507767 A JP 2007507767A JP 2007532605 A JP2007532605 A JP 2007532605A
- Authority
- JP
- Japan
- Prior art keywords
- epa
- dha
- content
- coronary
- ethyl ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 46
- 235000004626 essential fatty acids Nutrition 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 230000002265 prevention Effects 0.000 title claims abstract description 11
- 208000020401 Depressive disease Diseases 0.000 title claims abstract description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 90
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 239000002253 acid Substances 0.000 claims abstract description 24
- 125000004494 ethyl ester group Chemical group 0.000 claims abstract description 23
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 135
- 208000019553 vascular disease Diseases 0.000 claims description 51
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 claims 50
- 150000002148 esters Chemical class 0.000 abstract description 5
- 235000021323 fish oil Nutrition 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 47
- 239000002775 capsule Substances 0.000 description 18
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 description 14
- 208000024714 major depressive disease Diseases 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000006014 omega-3 oil Substances 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 101001000747 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 2A Proteins 0.000 description 1
- 101001000734 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 2B Proteins 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NCYSTSFUYSFMEO-OBLTVXDOSA-N PGI3 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C\C=C/CC)[C@H](O)C[C@@H]21 NCYSTSFUYSFMEO-OBLTVXDOSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031889 Vascular Depression Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- -1 cholesteryl ester Chemical class 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- ANOKPYOFAYATSS-UHFFFAOYSA-N propyl 4-oxocyclohexa-1,5-diene-1-carboxylate;sodium Chemical compound [Na].CCCOC(=O)C1=CCC(=O)C=C1 ANOKPYOFAYATSS-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101578 | 2004-04-16 | ||
| PCT/EP2005/004031 WO2005110393A1 (en) | 2004-04-16 | 2005-04-15 | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532605A true JP2007532605A (ja) | 2007-11-15 |
| JP2007532605A5 JP2007532605A5 (https=) | 2012-01-26 |
Family
ID=34928968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007507767A Pending JP2007532605A (ja) | 2004-04-16 | 2005-04-15 | 冠性心疾患または冠状動脈疾患を持つ患者の鬱病の予防および／または治療における必須脂肪酸 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1765319A1 (https=) |
| JP (1) | JP2007532605A (https=) |
| CN (1) | CN1942180A (https=) |
| AU (1) | AU2005244483B2 (https=) |
| BR (1) | BRPI0509878A (https=) |
| CA (1) | CA2504280A1 (https=) |
| IL (1) | IL178300A0 (https=) |
| MX (1) | MX291518B (https=) |
| RU (1) | RU2387448C2 (https=) |
| UA (1) | UA94693C2 (https=) |
| WO (1) | WO2005110393A1 (https=) |
| ZA (1) | ZA200607794B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
| ITMI20100961A1 (it) * | 2010-05-27 | 2011-11-28 | Erredue Spa | Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048788A1 (en) * | 1997-04-29 | 1998-11-05 | Scotia Holdings Plc | Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants |
| WO2002096408A1 (en) * | 2001-05-30 | 2002-12-05 | Laxdale Limited | Coenzyme q and eicosapentaenoic acid (epa) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
| GB9916536D0 (en) * | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
-
2005
- 2005-04-15 ZA ZA200607794A patent/ZA200607794B/en unknown
- 2005-04-15 JP JP2007507767A patent/JP2007532605A/ja active Pending
- 2005-04-15 BR BRPI0509878-5A patent/BRPI0509878A/pt not_active IP Right Cessation
- 2005-04-15 UA UAA200611798A patent/UA94693C2/ru unknown
- 2005-04-15 CA CA002504280A patent/CA2504280A1/en not_active Abandoned
- 2005-04-15 WO PCT/EP2005/004031 patent/WO2005110393A1/en not_active Ceased
- 2005-04-15 MX MXPA06011940 patent/MX291518B/es active IP Right Grant
- 2005-04-15 RU RU2006140277/14A patent/RU2387448C2/ru not_active IP Right Cessation
- 2005-04-15 AU AU2005244483A patent/AU2005244483B2/en not_active Ceased
- 2005-04-15 EP EP05779398A patent/EP1765319A1/en not_active Withdrawn
- 2005-04-15 CN CNA2005800114285A patent/CN1942180A/zh active Pending
-
2006
- 2006-09-26 IL IL178300A patent/IL178300A0/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048788A1 (en) * | 1997-04-29 | 1998-11-05 | Scotia Holdings Plc | Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants |
| WO2002096408A1 (en) * | 2001-05-30 | 2002-12-05 | Laxdale Limited | Coenzyme q and eicosapentaenoic acid (epa) |
Also Published As
| Publication number | Publication date |
|---|---|
| UA94693C2 (ru) | 2011-06-10 |
| CN1942180A (zh) | 2007-04-04 |
| AU2005244483A1 (en) | 2005-11-24 |
| RU2387448C2 (ru) | 2010-04-27 |
| CA2504280A1 (en) | 2005-10-16 |
| MX291518B (es) | 2011-10-31 |
| RU2006140277A (ru) | 2008-05-27 |
| ZA200607794B (en) | 2008-05-28 |
| BRPI0509878A (pt) | 2007-10-16 |
| WO2005110393A1 (en) | 2005-11-24 |
| IL178300A0 (en) | 2007-02-11 |
| AU2005244483B2 (en) | 2011-06-09 |
| MXPA06011940A (es) | 2006-12-15 |
| EP1765319A1 (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5441287B2 (ja) | 心血管事象を予防するための必須脂肪酸 | |
| MXPA05009432A (es) | Uso de acidos grasos omega-3 en el tratamiento de pacientes diabeticos. | |
| JP5827784B2 (ja) | ビタミンｋ２を含む医薬及び栄養補助製品 | |
| EP1310249B1 (en) | Use of polyunsatured fatty acids for the primary prevention of major cardiovascular events | |
| US20140107205A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| JP2004517148A (ja) | 心機能不全および心不全の治療における必須ｎ−３脂肪酸 | |
| AU2021201865A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| AU2015229240B9 (en) | Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances | |
| CA2905671A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| US20040235948A1 (en) | Treatment of diabetic patients with omega-3-fatty acids | |
| US8114906B2 (en) | Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease | |
| JP2007532605A (ja) | 冠性心疾患または冠状動脈疾患を持つ患者の鬱病の予防および／または治療における必須脂肪酸 | |
| JP2007532605A5 (https=) | ||
| US20250255842A1 (en) | Specialized pro-resolving lipid mediators for treating long covid-19 | |
| HK1099700A (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
| Aucamp et al. | Pilot trial to determine the efficacy of a low dose of fish oil in the treatment of angina pectoris in the geriatric patient | |
| GB2620543A (en) | Composition for use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080415 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101227 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110525 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110818 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111125 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20111125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120405 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130215 |